Clonidine

In the clinical application spectrum of central antihypertensive drugs, clonidine is a classic α-adrenoceptor agonist. It can stimulate the α₂ receptors on the postsynaptic membrane of the medulla oblongata, reduce the efferent of sympathetic nerve impulses, lower peripheral vascular resistance and heart rate, so as to achieve a stable antihypertensive effect. In addition to long-term control of hypertension, it can also be used for symptomatic treatment of migraine, menopausal hot flashes, and opioid withdrawal syndrome. The applicable population covers patients with essential hypertension, people under specific pain management, and subjects of addiction intervention treatment, making it an indispensable multi-indication variety in the primary clinical medication system.

At present, the global market size of clonidine preparations is approximately USD 420 million. Driven by factors such as the rising prevalence of hypertension and the expansion of off-label clinical applications in recent years, its compound annual growth rate has remained at around 3.8%. In terms of the domestic market, common clonidine tablets have been included in the national centralized procurement catalog, and the winning bid price has dropped by approximately 76% compared with that before the centralized procurement. The overall market supply is dominated by generic drugs, with stable demand for API and an annual consumption of more than 20 tons. There are fewer than 10 enterprises with approved API, and the market competition pattern is relatively concentrated.

The original developer of clonidine is Boehringer Ingelheim, with the original brand name Catapres®. The core compound patent expired worldwide in 1980. Currently, the main marketed dosage forms include oral tablets (0.1mg, 0.2mg, 0.3mg) and transdermal patches (1 patch per week, with release specifications of 0.1mg/24h, 0.2mg/24h, 0.3mg/24h). The original common tablets have been included in the FDA Reference Listed Drug Catalog and China's *Catalog of Reference Preparations for Chemical Drugs*. According to the domestic API registration platform, 6 enterprises have had their clonidine API registered with the status of "A" approved by the CDE. Meanwhile, the clonidine preparations approved in China cover multiple dosage forms such as common tablets, sustained-release tablets, and transdermal patches, which can fully meet the clinical medication needs. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO can provide a complete set of impurity reference standards for clonidine API. Relevant products meet the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA. Most impurities are in sufficient stock, and spot orders submitted before 16:00 can be shipped on the same day, which can provide stable and reliable reference standard support for generic drug consistency evaluation, quality research, and impurity control in the production process.